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doi:10.101Improved Outcomes Using Tacrolimus/Sirolimus for
Graft-versus-Host Disease Prophylaxis with a Reduced-
Intensity Conditioning Regimen for Allogeneic
Hematopoietic Cell Transplant as treatment
of Myelofibrosis
David S. Snyder, Joycelynne Palmer, Karl Gaal, Anthony S. Stein, Vinod Pullarkat,
Firoozeh Sahebi, Nyana Vora, Ryotaro Nakamura, Stephen J. FormanAllogeneic hematopoietic cell transplantation (HCT) using reduced-intensity conditioning (RIC) regimens is
a potentially curative treatment for patients (patients) with myelofibrosis (MF), as we and others have
reported. Nonrelapse mortality (NRM) from graft-versus-host disease (GVHD) and other complications
has limited the success of this approach. As part of an ongoing prospective research study at City of
Hope, a combination of tacrolimus/sirolimus 6 methotrexate (MTX) for GVHD prophylaxis has become
the standard treatment for our allogeneic HCT patients. In this report, we present results for 23 consecutive
patients, including extended follow up for 9 patients previously reported who received cyclosporine (CsA)/
mycophenolate moffetil (MMF)6MTX, and the current series of 14 patients who received tacrolimus/siro-
limus6MTX, and evaluate the impact of the GVHD prophylaxis regimen on the outcomes. Median follow-
up for alive patients was 29.0 months (9.5-97.0). The estimated 2-year overall survival (OS) for the CsA/MMF
cohort was 55.6% (confidence interval 36.0, 71.3), and for the tacrolimus/sirolimus cohort it was 92.9% (63.3,
98.8) (P5.047). The probability of grade III or IV acute GVHD (aGVHD) was 60% for the CsA/MMF patients,
and 10% for the tacrolimus/sirolimus group (P5.0102). No significant differences were seen for grade II to IV
aGVHD in the 2 groups. We conclude that the combination of tacrolimus/sirolimus6MTX for GVHD pro-
phylaxis in the setting of RIC HCT for MF appears to reduce the incidence of severe aGVHD and NRM, and
leads to improved OS compared to CSA/MMF6MTX.
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Allogeneic hematopoietic cell transplantation
(HCT) is the only known potentially curative treat-
ment for patients with primary or secondary myelofi-
brosis (MF) [1-4]. The applicability of this approach
to the population of patients with MF has been limitedCity of Hope Cancer Center, Departments of Hematolo-
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6/j.bbmt.2009.09.020by the availability of suitable donors, high rates of
morbidity, and nonrelapse mortality (NRM) associ-
ated with fully myeloablative (MA) conditioning regi-
mens, older age of the patients, and concerns about
delayed engraftment or graft failure in patients with
splenomegaly and fibrotic marrows. Increased success
in identifying well-matched unrelated donors (MUDs)
for patients who lack a matched-related donor has
helped to expand the pool of patients to whom alloge-
neic HCT can be offered. More recently, we [5] and
others have reported our experiences utilizing
reduced-intensity conditioning (RIC) regimens as an
encouraging strategy to reduce early morbidity and
treatment-related mortality (TRM)-associated with
allogeneic HCT and to extend the option of allogeneic
HCT to older patients [2,3,6-9].
The incidence of severe acute and chronic graft-
versus-host disease (aGVHD, cGVHD) leading to sig-
nificant morbidity and early NRM continues to be281
Table 1. Summary of Patient Characteristics and Transplant
Outcomes (n5 23)
Variable N (%)
Median
(Range)
Patient age at transplant (years) 58 (39-69)
Patient sex
Female 12 (52.2)
Male 11 (47.8)
Donor sex
Female 7 (30.4)
Male 16 (69.6)
Female donor to male recipient
transplants
2 (8.7)
Donor type
Sibling 8 (34.8)
Matched unrelated 15 (65.2)
Stem cell source
Bone marrow 2 (8.7)
Peripheral blood 21 (91.3)
CD34 cell dose 7.8 (1.1-20.0)
Time from diagnosis to transplant
(months)
21 (2.0-249.0)
Lille risk score at HCT
Low 1 (4.4)
Intermediate 12 (52.1)
High 10 (43.5)
Time to engraftment (days)
Absolute neutrophil count $500 16.5 (8.0-26.0)
Platelets $20 18.0 (10.0-110.0)
Transfusion-dependent post-HCT
Red blood cells 21 (91.3)
Platelets 15 (65.2)
GVHD prophylaxis
CSA, MMF, +/2MTX 9 (39.1)
Tacrolimus/sirolimus, +/2MTX 14 (60.9)
Acute GVHD
None 7 (30.4)
Grade I 4 (17.4)
II 7 (30.4)
III 2 (8.7)
IV 3 (13.0)
Time to acute GVHD onset (days) 32 (10-60)
Chronic GVHD
No 6 (30.0)
Yes 14 (70.0)
Limited 4 (28.6)
Extensive 10 (43.5)
Died# 100 Days 3
Time to chronic GVHD onset (days) 197 (100-351)
Constitutional symptoms
Yes 2 (8.7)
Fevers only 1
Night sweats only 1
No 21 (91.3)
Relapse post-HCT
Yes 1 (4.0)
No 22 (96.0)
Follow-up (months)
All patients 24.7 (0.7-97.6)
Alive 29.0 (9.5-97.6)
Dead 10 (0.7-21.6)
Number of death events post-HCT
Alive 18 (78.3)
Dead 5 (21.7)
Cause of death
(transplant related)
Yes 5 (100.00)
No 0 (0.00)
Cause of death
Graft failure, sepsis 1
GVHD, sepsis 1
GVHD, sepsis, graft failure 1
Infection 1
(Continued )
Table 1. (Continued )
Variable N (%)
Median
(Range)
Respiratory failure, alveolar
hemorrhage, Renal failure
1
CsA indicates cyclosporine; GVHD, graft-versus-host disease; HCT,
hematopoietic cell transplantation; MMF, mycophenolate mofetil;
MTX, methotrexate.
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Most studies have used some combination of cyclo-
sporine (CsA) or tacrolimus with methotrexate
(MTX) and/or mycophenolate mofetil (MMF) for
GVHD prophylaxis. Recently, a novel combination
of tacrolimus and sirolimus has been tested in place
of these more traditional immunosuppressive combi-
nations. There are data supporting the efficacy of ta-
crolimus/sirolimus in preventing clinically significant
aGVHD [10-12]. There are also concerns at some cen-
ters about increased toxicity from this combination in
the form of higher rates of sinusoidal obstructive syn-
drome (SOS; previously known as veno-occlusive dis-
ease) and thrombotic microangiopathy [13-15].
In an attempt to reduce the risk of mortality related
to GVHD, we modified our protocol to include tacro-
limus/sirolimus6MTX for GVHD prophylaxis in
place of CsA/MMF6MTX for patients undergoing
RIC allogeneic HCT utilizing granulocyte-colony
stimulating factor (G-CSF) primed peripheral blood
stem cells (PBSCs) from either matched sibling donors
orMUDs.We now present the results for this group of
14 patients, extend the follow-up for the original 9
patients previously reported, and evaluate the impact
of the GVHD prophylaxis regimen on outcomes.METHODS
Patients and GVHD Prophylaxis
Twenty-three consecutively treated patients with
MF who received RIC regimens for allogeneic HCT
were assessed as part of a formal treatment strategy ap-
proved by the institutional review board of City of
Hope (Duarte, CA). The first 9 patients were treated
between May 10, 2000, and February 11, 2004. The
second group of 14 patients was treated between July
15, 2005, andNovember 22, 2007. The date of analysis
was August 14, 2008.
The first 9 patients all received CsA/MMF as pro-
phylaxis against GVHD, whereas the second group of
14 patients received a combination of tacrolimus/siro-
limus. There were 7 female donors and 16 males, with
3 cases of female donor to male recipients (Table 1).
The median age was 58 years (range: 39-69) with 12
females, 11 males. Eighteen patients had primary
MF. Two of 9 CsA/MMF patients developed MF
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for GVHD Prophylaxissecondary to a prior myeloproliferative disorder and 3
of 14 tacrolimus/sirolimus patients had secondaryMF.
The Philadelphia chromosome and the bcr-abl gene
were excluded for all patients using standard methods.
JAK2 kinase V617F mutation analysis was available
pre-HCT only for 4 of 14 patients in the tacrolimus/
sirolimus cohort. Two of these 4 patients were positive
and 2 were negative. At the time of diagnosis, the risk
scores for the 17 patients with primary MF using the
new prognostic scoring system from the International
Working Group for Myelofibrosis Research and
Treatment (IWG-MRT) were: low for 3 patients; in-
termediate 1 for 7 patients; intermediate 2 for 3 pa-
tients; and high for 4 patients [16]. At the time of
HCT, the Lille risk score was high for 10 patients, in-
termediate for 12, and low for 1. Fifteen of the 23 pa-
tients (8/9 in the CsA/MMF cohort; 7/14 in the
tacrolimus/sirolimus cohort) had $1% blasts in the
PB before HCT, but all had\5% blasts in their pre-
HCT bone marrow (BM) samples. Twenty-two of
the 23 patients were classified as MF-3, and 1 patient
was classified as MF-2 [17]. Cytogenetic data were
available for 20 of the 23 patients in this study. Isolated
del(20q), which is considered a favorable prognostic
abnormalities along with isolated del(13q) [18] was
found in only 1 subject. Ten of these 20 patients had
normal cytogenetics, and 9 had a variety of other clonal
changes including 18 in 1 patient.
Eighteen of the 23 patients (9/9 of the patients in
the CSA/MMF cohort; 9/14 of the patients in the
tacrolimus/sirolimus cohort) had spenomegaly either
at the time of diagnosis or during the course of their
disease, ranging from 2-3 cm below the left costal mar-
gin to extending into the right pelvis. Nine of these 18
patients underwent splenectomy prior to HCT. The
decision to proceed to splenectomy was made by
each patient and physician team on a case-by-case
basis. In general, splenectomy was recommended for
patients with significant symptoms such as intractable
pain or inability to eat, who were deemed to be suitable
surgical candidates.Conditioning Regimen
The RIC regimen consisted of ffludarabine (Flu)/
melphalan (Mel) for 23 patients, including all 14 of
the tacrolimus/sirolimus patients, and Flu/total body
irradiation (TBI) for 1 patient in the CsA/MMF
cohort. That patient received Flu 30 mg/m2 per day
intravenously (i.v.) for 3 days on days 23 to 21, fol-
lowed by a single dose of TBI of 200 cGy on day 0.
The treatment schedule for the 8 patients who received
Flu/Mel and CsA/MMFwas Flu 25 mg/m2 per day i.v.
for 5 days given on days26 to22, Mel 140 mg/m2 i.v.
on day21, CSA 1.5 mg/kg i.v. starting on day21, and
MMF at 15 mg/kg i.v. twice a day starting 2 hours after
the end of the stem cell infusion on day 0.For the 14 patients who received Flu/Mel followed
by tacrolimus/sirolimus, the schedule was slightly dif-
ferent. The Flu was administered at 25 mg/m2 per day
i.v. for 5 days given on days29 to2 5, Mel 140 mg/m2
i.v. on day24, followed by tacrolimus 0.02 mg/kg/day
by continuous i.v. infusion starting on day23. Tacro-
limus dose was adjusted to maintain a whole blood
trough plasma concentration of 5-10 ng/mL when
used in combination with sirolimus. Sirolimus was
administered as an oral loading dose of 12 mg on day
23, followed by 4 mg orally daily. Sirolimus dose
was adjusted to maintain a whole blood trough plasma
concentration of 5-10 ng/mL. Six of the 7 recipients of
MUD stem cells who received CsA/MMF prophylaxis,
and 7 of 8 recipients of MUD stem cells who received
tacrolimus/sirolimus were also given MTX 5 mg/m2
i.v. on days 11, 13, and 16.
HLA Matching and Stem Cell Source
Eight patients received stem cell products from
HLA fully matched siblings (2/9 CsA/MMF patients;
6/14 tacrolimus/sirolimus patients) and 15 from
MUDs (7/9 CSA/MMF patients; 8/14 tacrolimus/
sirolimus patients). The MUDs were selected using
polymerase chain reaction (PCR) sequence-specific
primer or PCR sequence-specific oligonucleotide
probe techniques at HLA-A, -B, -C, -DR, and -DQ
loci. The donors for 10 patients were 10/10 matched;
micromismatched at HLA-DQB1 for 1 patient in the
first group; micromismatched at HLA-B and -DRB1
for the second donor for the 1 patient with graft failure
in the first group; micromismatched atHLA-A, -B, -C,
and -DQB1 for 1 patient in the first group; micromis-
matched at HLA-B and major mismatched at HLA-C
for 1 patient in the first group; micromismatched at
HLA-B and -DR for 1 patient in the second group;
and major mismatched at HLA-C for 1 patient in the
second group.
The source of stem cells was G 5 CSF primed PB
for 21 patients, and unprimed BM for 2 patients. The
median cell dose was 7.8 106 CD34 cells/kg.
Supportive Care
All patients were supported during the HCT
according to standard operating procedures including
the management of infectious complications, and the
use of low-dose continuous infusion of heparin for
prophylaxis against SOS.RESULTS
Engraftment
Neutrophil engraftment was defined as absolute
neutrophil count (ANC) $500 103/mL, achieved
and sustained for 3 consecutive days with no subse-
quent decline. Platelet engraftment was defined as
Tacro/Siro +/-MTXCSA/MMF +/-MTXTreatment Arm
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Figure 1. Days to aGVHD Grade III or greater stratified by GVHD
prophylaxis.
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the past 7 days. Twenty-two patients achieved ANC
engraftment by day 18 to 26 after HCT (median
16.5 days). One patient’s nadir was above an ANC of
500 during the transplant. One patient in the first
group never engrafted despite 3 transplant events.
He was very large (109 kg), had moderate splenomeg-
aly, and the CD34 cell counts were low in all 3 stem
cell products (0.7-2.7 106/kg). Eighteen of the 23
patients achieved platelet engraftment by day 110 to
110 (median 18.0 days). Four patients never engrafted
with platelets before they expired, and 1 patient’s nadir
was above 50,000/mL (Table 1). There was a trend
toward faster engraftment in splenectomized patients,
but thiswasnot statistically significant (datanot shown).Tacro/Siro +/-MTXCSA/MMF +/-MTXTreatment Arm
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Figure 2. NRM—100 days stratified by GVHD prophylaxis.Disease Status after HCT
The results of chimerism studies using FISH or
STR DNA analysis for the first 9 patients in this study
were previously reported [5]. Only 1 of those 9
patients, had relapsed transiently and then achieved
a complete remission again after withdrawal of immu-
nosuppressive therapy as the only intervention. All
5 surviving patients from that group remain disease
free at the time of this analysis.
For the tacrolimus/sirolimus cohort of patients,
STR analyses showed 100% donor cells at the time
of the latest assay in all 13 surviving patients. One of
these 14 patients relapsed at day 159, but achieved
a complete remission after withdrawal of immunosup-
pression and decitabine therapy.
The response of MF to HCT was assessed using
the European Myelofibrosis Network criteria [19].
For the 22 patients with MF-3 pre-HCT, post-HCT
samples were available for review for 20 of the patients
at varying time points ranging from 30 days to 3 years
(median 138 days). The post-HCT MF score was
MF-3 in 12 of 20, MF-2 in 6 of 20, and MF-1 in 2 of
20. One patient had MF-2 pre-HCT, and MF-0 at
392 days post-HCT.
The cellularity of the latest BM samples ranged
from\5 to 90% (median 30%).
For the 14 patients whose spleens were intact at the
time of HCT, the splenomegaly was reported as re-
solved in 7 at varying lengths of time post-HCT,
with the latest time of 594 days after HCT. There
were no data available for 6 patients, and study patient
4 died with splenomegaly still present at day121 after
his third HCT procedure. There was no difference in
outcomes for the patients who underwent splenectomy
before HCT versus those who did not. Only 2 patients
were known to be positive for the JAK2 V617F muta-
tion pre-HCT, and both of them were JAK2 negative
at days 1108 and 99 post-HCT, respectively. One
patient was JAK2 negative at day 1272 post-HCT,
but there were no data to compare pre-HCT. Twopatients were JAK2 negative pre-HCT and were not
tested post-HCT.GVHD and Other Regimen-Related Toxicities
aGVHD developed in 16 of 23 of the patients.
Maximum grade was grade I for 4 of 23, grade II for
7 of 23, grade III for 2 of 23, and grade IV for 3 of
23. The median time to onset of aGVHD was 32
days (range: 10-60). The probability of grade III or
IV aGVHD was 60% for the CsA/MMF patients,
and 10% for the tacrolimus/sirolimus group
(P5 .01) (see Figure 1). There was no significant dif-
ference in the incidence of grade II-IV aGVHD be-
tween the 2 groups of patients. Neither the type of
donor (sib versus MUD), the degree of HLA match-
ing, nor the gender of the donor were significant pre-
dictors of grade III or IV aGHVD (P5 .6, .73, and 1.0,
respectively).
Although the development of cGVHD was not
found to be significantly associated with OS, 5 of the
6 evaluable patients in the CSA/MMF cohort devel-
oped cGVHD (4/5 extensive) compared to 9 of 14
patients (6/9 extensive) in the tacrolimus/sirolimus
group.
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Figure 3. (A) OS. (B) OS stratified by GVHD prophylaxis.
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for GVHD ProphylaxisNone of the 23 patients developed clinically appar-
ent SOS or thrombotic microangiopathy (TMA).
Survival
The median follow-up for alive patients was 29.0
months (9.5-97.0). The 100-day TRM was 33.3% for
the CsA/MMF patients and 0 for the tacrolimus/siroli-
mus group (P5 .02) (see Figure 2). Five patients died: 3
of 9 of theCsA/MMFgroup fromGVHD6 infections
and 1 of 9 from graft failure with sepsis; 1 of 14 of the
tacrolimus/sirolimus group died from GVHD and
multiorgan failure. No patients died from relapsed
MF. The estimated 2-year OS for the CSA/MMF
cohort was 55.6% (confidence intervals 36.0, 71.3),
and for the tacrolimus/sirolimus cohort it was 92.9%
(63.3, 98.8) (p5 .047) (see Figure 3A and B). There
was no significant different in OS between patients
who underwent splenectomy pre-HCT versus those
who did not.DISCUSSION
Allogeneic HCT is the only potentially curative
therapy for patients with MF. The introduction of
RIC regimens has allowed investigators to extend
this modality to older patients. It is not clear whether
RIC offers an advantage over fully MA patients who
are younger [6,8], or whetherHCT is the optimal ther-apy over chemotherapy especially for younger patients
[20]. We have reported on our initial experience with
a group of 9 patients treated with RIC and CsA/
MMF6MTX for GVHD prophylaxis [5]. The main
cause of NRM in that group was GVHD and related
complications. In an effort to improve on those out-
comes, we changed the GVHD prophylaxis regimen
to tacrolimus/sirolimus6MTX. There have been en-
couraging reports about the efficacy of this regimen in
preventing GVHD [11,12,14]. There have also been
concerns about higher risks of developing SOS and
TMAwith this and related combinations [13,15]. Siro-
limus in particular has been implicated. Some contrib-
uting factors to these complications include the use of
busulfan or fully MA conditioning regimens [21].
All of our patients had varying degrees of spleno-
megaly, and 9 of them had undergone splenectomy
pre-HCT. There was no apparent impact of the pres-
ence or absence of the spleen on outcomes post-HCT,
including engraftment, GVHD, and survival, as has
been reported previously [22].
It is hypothesized that the main therapeutic benefit
of RIC HCT is the development of graft-versus-MF
effect post-HCT as an alloreactive immunologic reac-
tion. The fact that our surviving patients are all free of
disease is an affirmation of that postulate. The post-
HCT experiences of 2 of our patients, 1 in the first
cohort, and 1 in the second cohort, speak more clearly
to the benefits of the graft-versus-MF effect. Both
patients relapsed after HCT, and were salvaged to
a long-lasting remission by the removal of immuno-
suppression alone in the first of these 2 patients, and
by the combination of withdrawal of immunosuppres-
sion and the addition of the hypomethylating agent,
decitabine, in the second patient.
The discovery of the JAK2 V617F mutation in
patients with a variety of myeloproliferative disorders
including MF has enhanced our understanding of the
pathogenesis of these diseases, and has opened the
door to new targeted therapy [23]. There does not
appear to be an influence on outcomes after HCT
based on JAK2 mutation status [24], but PCR assays
for JAK2mutation offer a sensitive technique for mon-
itoring minimal residual disease (MRD), and for di-
recting post-HCT therapy for early relapse or
persistent disease [25-29]. We had limited data about
JAK2 mutation status in our patients pre-HCT. In
our 2 informative patients, the PCR for JAK2 muta-
tion was positive pre-HCT, and became negative
post-HCT, as an additional indicator of the curative
impact of this approach.
In this current report, we extend the follow-up of
the original series of 9 patients treated with RIC for
MF, and we contrast the results of this group to those
of a second series of 14 patients who received the same
conditioning regimen and stem cell source, but who
received tacrolimus/sirolimus6MTX instead of
286 Biol Blood Marrow Transplant 16:281-286, 2010D. S. Snyder et al.CsA/MMF6MTX. The main findings were that the
risk of developing grade III-IV aGVHD was signifi-
cantly lower in the second series of patients. This re-
duction in GVHD risk translated into a significant
reduction in 100-day NRM to 0%, and a significant
improvement in OS for the tacrolimus/sirolimus
group at 92.9%. The incidence of cGVHD remains
a significant issue even with the use of the tacroli-
mus/sirolimus combination. These results compare
very favorably to recent reports using either RIC or
MA conditioning regimens with OS ranging from 39
to 100% [1,2-4,7-9].ACKNOWLEDGMENTS
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